Vyvgart Crosses the Antibody Line in Seronegative Myasthenia Gravis
Phase 3 ADAPT SERON data show efgartigimod improves function in seronegative generalized myasthenia gravis, with FDA priority review potentially expanding targeted treatment options for underserved patients.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.